Putative mechanism(s) of action
Effector
cell
ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity
FcγRIIIa
Complement
Increased direct cell death
Type II antibody & elbow-hinge
modification
Increased ADCC
Higher affinity to the 'ADCC receptor'
FcγRIIIa (GlycoMab TM technology) &
Reduced CD20 internalization (?)
Reduced CDC activity
Type II antibody
Enhanced activity in combination
with chemotherapy
Type II CD20 antibody